Investigation of solid lipid nanoparticles as oral delivery of Paclitaxel for enhanced absorption.

DESAI, Jagruti; PATEL, Swayamprakash; MANJAPPA, Arehalli; PATEL, Alkesh; PATEL, Twinkle

Paclitaxel is an anticancer drug that has poor oral bioavailability (>10%) because of its poor solubility in aqueous medium, poor permeability, and is a substrate of poly-glycoprotein and CYP450 metabolism. The current study intends to create Paclitaxel-loaded solid lipid nanoparticles (SLNs) to overcome these limitations. The nanoparticles were formulated through an emulsification-solvent evaporation method and freeze-dried. To optimize the nanoparticle formulation, the box-behnken design was adopted. The final formulation had a particle size of 190 nm with 88.79% drug entrapment. The in-vitro release study for 24 hr showed a 1.6-fold increase in drug release in the dissolution of paclitaxel from SLNs in comparison to drug suspension. A 2.4-fold increase in bioavailability of the drug in-vivo was obtained compared to the commercial formulation. Thus, a promising carrier for PTX was developed that could increase its efficiency and alleviate the dose-dependent side effects.

DRUG solubility; INTESTINAL barrier function; DRUG bioavailability; M cells; ANTINEOPLASTIC agents; PACLITAXEL

Journal of Research in Pharmacy, 2024, Vol 28, Issue 3, p781

2630-6344

Academic Journal

10.29228/jrp.739